Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c
March 10, 2022 7:02 AM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.42), $0.18 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.43 million versus the consensus estimate of $18.9 million.
The Company is providing the following financial guidance:
Net product revenue of $105 million to $120... More